Document Detail

Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents.
MedLine Citation:
PMID:  22495576     Owner:  NLM     Status:  Publisher    
Therapy targeting tumor blood vessels ought to inhibit tumor growth. However, tumors become refractory to antiangiogenic drugs. Therefore, therapeutic solutions should be sought to address cellular resistance to antiangiogenic therapy. In this regard, reversal of the proangiogenic and immunosuppressive phenotype of cancer cells, and the shift of the tumor microenvironment towards more antiangiogenic and immune-stimulating phenotype may hold some promise. In our study, we sought to validate the effects of a combination therapy aimed at reducing tumor blood vessels, coupled with the abrogation of the immunosuppressive state. To achieve this, we developed an oral DNA vaccine against endoglin. This antigen was carried by an attenuated Salmonella Typhimurium and applied before or after tumor cell inoculation into immunocompetent mice. Our results show that this DNA vaccine effectively inhibited tumor growth, in both the prophylactic and therapeutic settings. It also activated both specific and nonspecific immune responses in immunized mice. Activated cytotoxic T-lymphocytes were directed specifically against endothelial and tumor cells overexpressing endoglin. The DNA vaccine inhibited angiogenesis but did not affect wound healing. In combination with interleukin-12-mediated gene therapy, or with cyclophosphamide administration, the DNA vaccine resulted in reduced microvessel density and lowered the level of T(reg) lymphocytes in the experimental tumors. This effectively inhibited tumor growth and prolonged survival of the treated animals. Polarization of tumor milieu, from proangiogenic and immunosuppressive, towards an immunostimulatory and antiangiogenic profile represents a promising avenue in anticancer therapy.Gene Therapy advance online publication, 12 April 2012; doi:10.1038/gt.2012.28.
M Jarosz; J Jazowiecka-Rakus; T Cichoń; M Głowala-Kosińska; R Smolarczyk; A Smagur; S Malina; A Sochanik; S Szala
Related Documents :
22340586 - Glycine decarboxylase cleaves a "malignant" metabolic path to promote tumor initiation.
22686936 - Nanoparticle delivery of pooled sirna for effective treatment of non-small cell lung ca...
22445386 - Synthesis and comparative assessment of a labeled rgd peptide bearing two different (99...
22729866 - Acb-pcr measurement of h-ras codon 61 caa→cta mutation provides an early indication o...
12403556 - Antiangiogenesis in neurofibromatosis 1.
18604176 - The shca adaptor protein is a critical regulator of breast cancer progression.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-4-12
Journal Detail:
Title:  Gene therapy     Volume:  -     ISSN:  1476-5462     ISO Abbreviation:  -     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-4-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9421525     Medline TA:  Gene Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Center for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  CN-assisted oxidative cyclization of cyano cinnamates and styrene derivatives: a facile entry to 3-s...
Next Document:  Induced electric field and current density patterns in bone fractures.